Retina/Vitreous News

ATSN-201 received orphan drug designation from the FDA for the treatment of X-linked retinoschisis, according to a press release from Atsena Therapeutics.

Patients with preclinical Alzheimer’s disease had significantly greater putative retinal gliosis compared with controls, according to study results published in Investigative Ophthalmology & Visual Science.

The FDA granted 510(k) clearance for OCT angiography on the robotic Maestro2 OCT color fundus camera system, according to a press release from Topcon Healthcare.

Viridian Therapeutics reported positive topline data from the phase 3 THRIVE clinical trial of veligrotug for the treatment of active thyroid eye disease.

CARLSBAD, Calif. — In this Healio Video Perspective from the Women in Ophthalmology Summer Symposium, Lisa M. Nijm, MD, JD, discusses the burden of thyroid eye disease and how it affects quality of life.

The FDA cleared an investigational new drug application for OpCT-001, an investigational cell therapy for the treatment of primary photoreceptor diseases, according to a press release from BlueRock Therapeutics.

Less than 25% of patients with thyroid eye disease who underwent a full course of treatment with Tepezza required re-treatment, according to a study published in Ophthalmology.

Retinal ganglion cell layer thickness was significantly reduced in patients with severe COVID-19, which indicates an affinity for nerve cells, according to research published in the Open Journal of Ophthalmology.

Delayed diagnosis of congenital optic disc abnormalities increases the risk for complications and may affect visual prognosis, according to a study published in the Open Journal of Ophthalmology.